ACP
MREO

Arcus Capital Partners’s Mereo BioPharma MREO Stock Holding History

Arcus Capital Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,000
Closed -$19.4K – 130
2023
Q3 		$19.4K Buy
+15,000
New +$19.9K 0.01% 123

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Arcus Capital Partners's MREO Position: Q4 2023 in Review

Arcus Capital Partners sold out of Mereo BioPharma (MREO) in Q4 2023, closing a stake of 15,000 shares — an estimated $19.4K sold.

Arcus Capital Partners first reported a position in MREO in Q3 2023 and held it in 1 quarter. The position peaked at $19.4K in Q3 2023. 64 funds tracked by Wall St. Rank hold MREO as of Q4 2023.

  • Arcus Capital Partners reported no remaining Mereo BioPharma position as of Q4 2023 after selling out during the quarter.
  • Arcus Capital Partners sold 15,000 Mereo BioPharma shares in Q4 2023, an estimated $19.4K.
  • Arcus Capital Partners first reported a position in Mereo BioPharma in Q3 2023 and held it in 1 quarter.
  • Arcus Capital Partners's Mereo BioPharma position peaked at $19.4K in Q3 2023.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2023.

Based on Arcus Capital Partners's 13F filing for Q4 2023, filed 23 Jan 2024.